Pharmexa acquires patent estate from Vectron Therapeutics

Published: 6-Jan-2005

Pharmexa has acquired a portfolio of intellectual property rights within the field of immunotherapy from Vectron Therapeutics, a German biotech company in liquidation.


Pharmexa has acquired a portfolio of intellectual property rights within the field of immunotherapy from Vectron Therapeutics, a German biotech company in liquidation.

Pharmexa operates in the field of active immuno-therapy for the treatment of serious chronic disease, and the acquired technologies, which include both issued and pending patent applications, cover novel targeted liposomal delivery systems and recombinant antibody-like proteins known as single chain diabodies. Liposomes are a well-known effective delivery system that can be formulated with either AutoVaca Protein or AutoVaca DNA pharmaccines. Diabodies are small antibody-like fragments that have many capabilities, including passive immunotherapy.

'In the mid- to long-term, these technologies could potentially complement our immunotherapy platform in a number of interesting ways, while right now representing a very inexpensive opportunity for us,' said Pharmexa's ceo Jakob Schmidt.

You may also like